A recent study published in the journal Nature Genetics has brought the Bipolar Workgroup of the international Psychiatric Genomics Consortium (PGC), of which BDRN is a key member, one step closer to understanding the neurobiology of bipolar disorder.
We are striving to better understand the genetics behind bipolar disorder. Together we studied over 7.5 million common variations in the DNA sequence from almost 415,000 people, over 40,000 of whom have bipolar disorder.
The bipolar disorder DNA samples were collected by researchers from more than 200 institutions all over the world. Over 6,000 samples were from BDRN participants. BDRN is one of the largest and most established continuous bipolar disorder study in the world.
Professor Lisa Jones, who leads BDRN at the University of Worcester, said about the research: “The Bipolar Disorder Research Network (BDRN) is the largest contributor of bipolar participants to this landmark world-wide analysis and we are indebted to everyone who has volunteered to help with BDRN over the last 25 years.”
Dr Arianna Di Florio, BDRN researcher at Cardiff University, explained: “DNA is the instruction manual your body uses to develop and function. Each person’s DNA varies slightly from everyone else’s and this is what makes us different.”
By comparing the DNA variations in people with and without bipolar disorder, the study identified variations that point to systems within the brain that are important for communication between neurons, which are the cells responsible for carrying information through the brain and nervous system so that we can react to our environment.
Dr Di Florio continued: “This research found more than double the number of DNA variations that influence one’s risk for the disorder since our last paper. We are therefore another step closer to understanding the neurobiology of bipolar disorder and will continue to focus on improving this in our future work.”
Professor Andrew McQuillin, who headed the University College London arm of the study, added: “This study found DNA variations linked to bipolar disorder that are relevant in neuron communication and calcium signalling. This points to the possibility of repurposing drugs already used for the circulatory system for bipolar disorder treatments.”
The actual effectiveness of these drugs for bipolar disorder remains unknown however and requires further research before any recommendations can be made. Other possible genetic variations that might be targetable by drugs were identified and may be of interest for researchers going forward.
The study also found overlaps between the biology of bipolar disorder and that of other psychiatric disorders such as depression and schizophrenia and, to a lesser extent, that of sleep habits and alcohol and substance usage.
Our findings provide researchers with important information to consider for a wide range of follow-up studies, from the biological mechanisms of bipolar disorder to its definition and treatment options.
BDRN and the PGC will continue to build on this work with additional cases and analyses of the data, hopefully moving towards a better understanding of bipolar disorder.
